Next Article in Journal
Optimization of the Solvent and In Vivo Administration Route of Auranofin in a Syngeneic Non-Small Cell Lung Cancer and Glioblastoma Mouse Model
Next Article in Special Issue
Targeting OPA1-Mediated Mitochondrial Fusion Contributed to Celastrol’s Anti-Tumor Angiogenesis Effect
Previous Article in Journal
Enzymatic Crosslinked Hydrogels of Gelatin and Poly (Vinyl Alcohol) Loaded with Probiotic Bacteria as Oral Delivery System
Previous Article in Special Issue
Mitochondrial Dysfunction: Pathophysiology and Mitochondria-Targeted Drug Delivery Approaches
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceutics
Volume 14
Issue 12
10.3390/pharmaceutics14122760
Review Report
pharmaceutics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

The Therapeutic Strategies Targeting Mitochondrial Metabolism in Cardiovascular Disease

Pharmaceutics 2022, 14(12), 2760; https://doi.org/10.3390/pharmaceutics14122760
by Xiaoyang Huang 1,†, Zhenhua Zeng 2,†, Siqi Li 1,3, Yufei Xie 1 and Xiaoyong Tong 1,4,*
Reviewer 1:
Muhammad Akhtar
Reviewer 2: Anonymous
Pharmaceutics 2022, 14(12), 2760; https://doi.org/10.3390/pharmaceutics14122760
Submission received: 31 October 2022 / Revised: 2 December 2022 / Accepted: 7 December 2022 / Published: 9 December 2022
(This article belongs to the Special Issue Advances in Mitochondria-Targeted Drug Delivery)

Round 1

Reviewer 1 Report

The paper is sound in providing therapeutic strategies to CVD. It requires illustrations & figures to well explain the mechanism of mitochondrial pathway. Review article is incomplete without proper figures. 

References are good in number but where therapeutic strategies are mentioned add recent references related to clinical trials.

Mention the impact and significance of novel therapeutic strategies compared to older techniques.

 

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

The authors in the manuscript review the role of mitochondrial metabolism in the prevention and treatment of CVD, with a specific overview for the mitochondria-targeted therapeutic strategies.
In the first part of manuscript the authors describe the causes of CVD and the possible role of mitochndrial disfunctions that underpinning the cardiovascular diseases.
The second part the ptential mitochondrial target for theraputic treatements of CVD, most of them are antioxidants are listed In the third part of review the authors describe strategies for mitochondria-targeted gene therapies.
In particular authors overview the current technical for mitochondrial gene therapies and their limitations.

The review is well organized and it should be of great interest for the readers.


Minor issues

page 4, second paragraph: word "pyruvate" is reported two times.
page 6, second paragraph: CPT1 is not a transporter, but an enzyme that catalyzes the transfer of acyl group from acyl-CoA to carnitine.
page 10 "5.1.3[. Ca2+]", should be "5.1.3.[Ca2+]"
page 10, last paragraph, CoQ10 is not an enzyme, but it is an essential cofactor in the mitochondrial electron transport chain.
page 14, The authors report that the gene therapies have effects on the rescue of mtDNA mutations.
The authors should report also, if the gene therapies rescue the cardiovascular phenotypes.

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Back to TopTop